Dec. 9 at 12:42 PM
$CARL drops 27.5% post-launch — what's behind the plunge? 📉
Despite the launch of its cervical fusion platform with strong clinical backing and favorable reimbursement, shares fell sharply. CARL's stock has declined 15.1% compared with the industry since its IPO.
Understand the risks before investing in CARL 👉 https://www.zacks.com/stock/news/2801398/carl-launches-aprevo-cervical-platform-for-personalized-spine-surgery?cid=sm-stocktwits-2-2801398-body-23915&ADID=SYND_STOCKTWITS_TWEET_2_2801398_BODY_23915